Jefferies Defends Enhabit Home Health & Hospice (EHAB): 'Sell-Off Unwarranted Given Stabilizing KPIs, Defensiveness vs DC, Valuation'
Jefferies analyst Brian Tanquilut reiterated a Buy rating and $9.50 price target on Enhabit Home Health & Hospice (NYSE: EHAB)The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)